PMID- 23277249
OWN - NLM
STAT- MEDLINE
DCOM- 20130612
LR  - 20181202
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 33
IP  - 1
DP  - 2013 Feb
TI  - Neuropsychiatric adverse events of varenicline: a systematic review of published 
      reports.
PG  - 55-62
LID - 10.1097/JCP.0b013e31827c0117 [doi]
AB  - INTRODUCTION: Over the past years, the impact of varenicline in patients with 
      mental illness has been debated as serious neuropsychiatric adverse events (AEs) 
      have been reported with varenicline use. AIM: To identify and summarize published 
      case reports of neuropsychiatric AEs ascribed to varenicline and to determine 
      potential risk factors for these AEs. METHODS: A literature search of MEDLINE, 
      the Cochrane Library, EMBASE, and PsychInfo database was conducted for case 
      reports concerning the neuropsychiatric AEs of varenicline published in English 
      from 2006 (approval year by the US Food and Drug Administration and the Dutch 
      Medicines Evaluation Board) to January 1, 2012. RESULTS: We identified 25 
      published cases. In most reports, patients had been admitted to psychiatric 
      hospitals with serious neuropsychiatric AEs due to varenicline. The average 
      patient age was 46.4 years, and 56% were men; 68% of patients had a psychiatric 
      history. The onset of symptoms started 2 days to 3 months after the initiation of 
      varenicline. One report described completed suicide in a man with no psychiatric 
      history. In most cases (84%), the neuropsychiatric symptoms resolved after the 
      discontinuation of varenicline. Analysis of all reports using the Naranjo 
      causality scale, a method for estimating the probability of adverse drug 
      reactions, indicated probable causality in 76% of the cases and definite 
      causality in 12% of cases. CONCLUSION: Varenicline is associated with an 
      increased risk of serious neuropsychiatric AEs, especially in patients with a 
      psychiatric illness. It is strongly recommended that varenicline be administered 
      only to mentally stable patients and under close monitoring.
FAU - Ahmed, Amir I A
AU  - Ahmed AI
AD  - Department of Elderly, Vincent van Gogh Institute for Psychiatry, Venray, The 
      Netherlands. amirahmed1@hotmail.com
FAU - Ali, Abdullah N A
AU  - Ali AN
FAU - Kramers, Cees
AU  - Kramers C
FAU - Harmark, Linda V D
AU  - Harmark LV
FAU - Burger, David M
AU  - Burger DM
FAU - Verhoeven, Willem M A
AU  - Verhoeven WM
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Benzazepines)
RN  - 0 (Nicotinic Agonists)
RN  - 0 (Quinoxalines)
RN  - W6HS99O8ZO (Varenicline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Benzazepines/*adverse effects
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Disorders/*chemically induced/diagnosis/psychology
MH  - Middle Aged
MH  - Nicotinic Agonists/*adverse effects
MH  - Quinoxalines/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - Smoking Cessation/*methods
MH  - *Smoking Prevention
MH  - Time Factors
MH  - Varenicline
MH  - Young Adult
EDAT- 2013/01/02 06:00
MHDA- 2013/06/13 06:00
CRDT- 2013/01/02 06:00
PHST- 2013/01/02 06:00 [entrez]
PHST- 2013/01/02 06:00 [pubmed]
PHST- 2013/06/13 06:00 [medline]
AID - 10.1097/JCP.0b013e31827c0117 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2013 Feb;33(1):55-62. doi: 10.1097/JCP.0b013e31827c0117.